COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus

A Prospective, Non-interventional, Observational, Multi-center Trial to Evaluate Compliance and Efficacy in Mono and Combination Treatment of Candesartan Cilexetil(Atacand)/ Candesartan Cilexetil 16mg, Hydrochlorothiazide 12.5mg(Atacand Plus) in Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00526279

Acronym

COMBAT

Enrollment

9000

Registered

2007-09-10

Start date

2007-06-30

Completion date

2008-08-31

Last updated

2010-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, Atacand/Atacand plus, COMBAT, Compliance, Naturalistic, Observational

Brief summary

To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients who have consented to participation/data release in this study 2. Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision

Exclusion criteria

1. Secondary hypertension requiring therapy other than antihypertensive medication 2. Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician 3. Women in pregnancy or lactation 4. Patients enrolled in any other studies

Countries

South Korea

Outcome results